Guiding patient care in ambiguous melanocytic lesions

MyPath Melanoma is a gene expression profile (GEP) test that provides clarity in managing patients with ambiguous melanocytic lesions.

GEP provides objective information to clarify malignant potential

When patients are diagnosed with routine nevi or malignant melanoma, the treatment plans are clearly defined by medical guidelines. However, there is a lack of clarity and standardization in the most appropriate management plan for patients with ambiguous, atypical, and abnormal melanocytic lesions. MyPath Melanoma can clarify the underlying malignant potential of the lesion allowing providers to escalate or de-escalate surgical treatment and follow-up frequency.

Aiding dermatology providers in determining malignant potential

In recent studies and case reports, 1,2 ancillary diagnostic GEP testing has aided dermatologists in determining the malignant potential of these challenging melanocytic lesions. This allows providers to confidently align patient management to the malignant potential as determined by GEP.

MyPath Melanoma GEP testing provides an objective assessment of the expression levels of 23 genes and applies a proprietary algorithm to classify the lesion as suggestive of benign or suggestive of malignant.3 Numerous studies have demonstrated high sensitivity and specificity 4-8 and clinical utility 9–12 of GEP testing for dermatology providers.

Examples of cases that are appropriate for testing

Borderline or uncertain diagnosis

  • Atypical intraepidermal melanocytic proliferation (AIMP)

  • Borderline or severely dysplastic nevus

  • Cannot exclude melanoma in situ

  • Cannot exclude early-evolving invasive melanoma

Uncertain malignant potential

  • Atypical Spitz tumor

  • Melanocytic tumor of uncertain malignant potential (MELTUMP)

Conflicting clinical and/or histopathological features

  • Highly concerning clinical history or dermoscopic features

  • Critical mismatch between clinical and histopathological findings

  • Equivocal, ambigious, or indeterminate result from ancillary testing such as IHC, FISH, or CGH

Treatment recommendation

  • Surgical management in cosmetically sensitive areas

  • Follow-up management decisions

  • Recommendation to re excise without definitive diagnosis for melanoma

Explore case studies

Get started with MyPath Melanoma